Clinical Research Protein RNA 
pharmaphorum
JANUARY 5, 2022
The new vaccine differs from the currently approved shots because it delivers antigens for both the spike protein and other proteins found in SARS-CoV-2. That could mean it is less susceptible to the loss of efficacy to vaccines that can occur when there are changes in the spoke protein – as witnessed with the new Omicron variant.
XTalks
SEPTEMBER 4, 2024
Alnylam Pharmaceuticals announced promising results from its HELIOS-B Phase III clinical trial evaluating vutrisiran, an investigational RNA interference (RNAi) therapeutic for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). As of March 2024, the FDA has approved six small interfering RNA (siRNA) therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JUNE 18, 2024
.” — Aki Ko Additionally, Elixirgen Therapeutics has unveiled promising preclinical results for its Bobcat mRNA technology at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida.
Worldwide Clinical Trials
MAY 30, 2024
Tofersen (Intrathecal injection) This is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. Other researchers are investigating approaches that use AAV-mediated trophic support and antibody-based therapies, such as vaccines and small molecule drugs, to modify various protein expressions.
Roots Analysis
AUGUST 28, 2022
Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. 70+ spatial Genomics solutions are developed by industry and non-industry players.
Find Me Cure
OCTOBER 13, 2019
This Breast Cancer Awareness Month we’d like to talk about emerging areas in metastatic breast cancer treatment since clinical research has come so far in recent years. The team sequenced DNA and RNA from her tumour and from healthy tissue to find out which unique to her case mutations they needed to target.
XTalks
NOVEMBER 7, 2022
“Liquid biopsies have demonstrated promising activity in multiple clinical settings, but the great enthusiasm and expectations around them can be harmful if not adequately managed,” said Dr. El Mustapha Bahassi, PhD, Director, Clinical Laboratory Sciences, at the global clinical research organization (CRO) Medpace.
Expert insights. Personalized for you.
126 
Let's personalize your content